UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.
How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ucb's score of 89 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, UCB reported total carbon emissions of approximately 790,866,000 kg CO2e, with significant contributions from Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions were about 21,718,000 kg CO2e, while Scope 2 emissions totalled approximately 16,291,000 kg CO2e. The majority of emissions stemmed from Scope 3, amounting to around 769,143,000 kg CO2e, which includes substantial figures from purchased goods and services (approximately 692,013,000 kg CO2e) and business travel (about 24,873,000 kg CO2e). UCB has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 73% by 2030 from a 2019 base year, and to achieve net-zero emissions across all scopes by 2045. Additionally, UCB targets a 90% reduction in absolute Scope 1, 2, and 3 emissions by 2045, compared to the 2019 baseline. The company also commits that 60% of its suppliers by emissions will have science-based targets by 2025. These initiatives reflect UCB's dedication to addressing climate change and reducing its carbon footprint, aligning with industry standards for sustainability and environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 34,733,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 31,367,000 | 00,000,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 0,000 |
Scope 3 | - | - | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ucb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.